Black Diamond Therapeutics Inc
NASDAQ:BDTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 5-Year Average (0.2), the stock would be worth $0.22 (93% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.5 | $3.06 |
0%
|
| 5-Year Average | 0.2 | $0.22 |
-93%
|
| Industry Average | 14.3 | $17.66 |
+477%
|
| Country Average | 19.6 | $24.27 |
+693%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$7.9m
|
/ |
Jan 2026
$19.9m
|
= |
|
|
$7.9m
|
/ |
Dec 2026
$-49.8m
|
= |
|
|
$7.9m
|
/ |
Dec 2027
$-80.5m
|
= |
|
|
$7.9m
|
/ |
Dec 2028
$-80.4m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Black Diamond Therapeutics Inc
NASDAQ:BDTX
|
174.8m USD | 2.5 | 7.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.4B USD | 20.1 | 87.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
191.5B USD | 14.3 | 24.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.8B USD | 15.5 | 20.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD | 22.2 | 28.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.3B USD | 15 | 17.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.4B EUR | 44.6 | 40.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 13.7 | 32.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Black Diamond Therapeutics Inc
Glance View
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 88 full-time employees. The company went IPO on 2020-01-30. The firm is focused on the discovery and development of small molecule, MasterKey therapies. The Company’s technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Its lead product candidate, BDTX-189, is designed as an orally available, irreversible small molecule inhibitor that targets a spectrum of 48 non-canonical and canonical driver mutations of the ErbB kinases epidermal growth factor receptor (EGFR) and HER2. BDTX-1535 is designed as a brain-penetrant small molecule inhibitor that targets a spectrum of EGFR mutations, including allosteric and canonical mutations. The company also has early-stage programs, such as B-Raf Proto-Oncogene (BRAF), and fibroblast growth factor receptor (FGFR).
